Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc.
Your view on ACHV
Overview
What the company does, where it operates, and who runs it.
About Achieve Life Sciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. B. Stewart
- Headquarters
- 1040 West Georgia Street, Vancouver, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. B. Stewart
- Headquarters
- 1040 West Georgia Street, Vancouver, BC, CA
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Achieve Life Sciences, Inc. from FRC's valuation model, read against the market price. ACHV last traded at $6.78; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Achieve Life Sciences, Inc.. Starting points for Achieve Life Sciences, Inc.: EPS -$1.32, beta 2.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Achieve Life Sciences, Inc.. Achieve Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Achieve Life Sciences, Inc.. Trailing twelve-month EPS for Achieve Life Sciences, Inc. stands at -$1.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$14.80
average of 5 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy4
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2015 | Next QtrMar 2016 | Current YearFY Dec 2016 | Next YearFY Dec 2017 |
|---|---|---|---|---|
| Avg. estimate | -$0.18 | -$12.46 | -$1,870.00 | -$1,936.00 |
| Low estimate | -$0.22 | -$14.95 | -$4,360.83 | -$4,514.74 |
| High estimate | -$0.14 | -$9.97 | -$423.72 | -$438.68 |
| No. of analysts | 15 | 12 | 3 | 2 |
| Year-ago EPS | — | — | — | — |
| Growth | — | — | — | — |
Revenue Estimate
| Revenue | Current QtrSep 2015 | Next QtrMar 2016 | Current YearFY Dec 2016 | Next YearFY Dec 2017 |
|---|---|---|---|---|
| Avg. estimate | $7.16M | $2.86M | $4.78M | $4.50M |
| Low estimate | $5.73M | $2.29M | $1.94M | $1.82M |
| High estimate | $8.59M | $3.43M | $9.68M | $9.11M |
| No. of analysts | 15 | 12 | 1 | 2 |
| Year-ago revenue | — | — | — | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 17, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Achieve Life Sciences, Inc.. Achieve Life Sciences, Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- QNTMQuantum BioPharma Ltd.Biotechnology$9M
More Biotechnology companies
- LGNDLigand Pharmaceuticals IncorporatedNASDAQ$6.0B
- LGVNLongeveron Inc.NASDAQ$7M
- LIANYLianBioOTC$10M
- LIFSLife Stem Genetics Inc.OTC$9,168
- LIMNLiminatus Pharma, Inc. Class A Common StockNASDAQ$4M
- LIMNWLiminatus Pharma, Inc. WarrantsNASDAQ$941,853
- LIPOLipella Pharmaceuticals Inc.NASDAQ$2M
- LITSLite Strategy, Inc.NASDAQ$26M
- LKFTLakefront Biotherapeutics N.V.NASDAQ$2.3B
- LNAILunai Bioworks Inc.NASDAQ$829,677
- LOBE.CNLobe Sciences Ltd.CNQ$10M
- LOBEFLobe Sciences Ltd.OTC$8M
ETFs holding Achieve Life Sciences, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.01%
- VTWOVanguard Russell 2000 ETF$16.6B in assets0.02%
- FESMFIDELITY ENHANCED SMALL CAP ETF$6.7B in assets0.03%
- DWASInvesco Dorsey Wright SmallCap Momentum ETF$376M in assets0.32%
- VFMOVanguard U.S. Momentum Factor ETF$1.9B in assets0.08%
- VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.05%
- GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETF$1.0B in assets0.02%
Largest holders first, then the funds most concentrated in ACHV.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Achieve Life Sciences, Inc., and how their positions are changing. At a $697.7M market value, institutional positions materially move Achieve Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Achieve Life Sciences, Inc. executives and directors. Shares of Achieve Life Sciences, Inc. have traded between $1.84 and $5.78 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Achieve Life Sciences, Inc.. Coverage tracks Achieve Life Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Achieve Life Sciences, Inc.